This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n24http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00051/identifier/genbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00051/identifier/uniprotkb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00051/identifier/wikipedia/
n4http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00051/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n7http://www.drugs.com/cdi/
n15http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00051/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00051/identifier/national-drug-code-directory/
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00051
rdf:type
n5:Drug
n5:description
Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
n5:dosage
n23:271B41EA-363D-11E5-9242-09173F13E4C5 n23:271B41E8-363D-11E5-9242-09173F13E4C5 n23:271B41E9-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# PDB sequence "Link":http://www.rcsb.org/pdb/download/downloadFile.do?fileFormat=FASTA&compression=NO&structureId=1IGT # Patent Information "Link":http://www.freepatentsonline.com/6090382.html
n5:group
approved
n5:halfLife
10-20 days.
n5:indication
For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
owl:sameAs
n4:DB00051 n27:DB00051
dcterms:title
Adalimumab
adms:identifier
n14:PA10004 n16:P01857 n17:J00228 n18:0074-3799-02 n20:DB00051 n26:Adalimumab
n5:mechanismOfAction
Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.
n5:packager
n21:271B41DF-363D-11E5-9242-09173F13E4C5 n21:271B41E0-363D-11E5-9242-09173F13E4C5
n5:patent
n8:2243459
n5:synonym
Ig gamma-1 chain C region
n11:hasAHFSCode
n22:92-00-00
n9:hasConcept
n10:M0422769
foaf:page
n7:adalimumab.html n24:humira.htm
n5:Molecular-Formula
n15:271B41EE-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n15:271B41ED-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:L04AB04
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
331731-18-1
n5:category
n5:clearance
* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]
n5:containedIn
n19:271B41E6-363D-11E5-9242-09173F13E4C5 n19:271B41E7-363D-11E5-9242-09173F13E4C5 n19:271B41E4-363D-11E5-9242-09173F13E4C5 n19:271B41E5-363D-11E5-9242-09173F13E4C5 n19:271B41E2-363D-11E5-9242-09173F13E4C5 n19:271B41E3-363D-11E5-9242-09173F13E4C5 n19:271B41E1-363D-11E5-9242-09173F13E4C5
n5:Hydrophobicity
n15:271B41EB-363D-11E5-9242-09173F13E4C5
n5:Isoelectric-Point
n15:271B41EC-363D-11E5-9242-09173F13E4C5